Kewalramani Reshma's Insider Trades & SAST Disclosures
Kewalramani Reshma's most recent trade in Vertex Pharmaceuticals, Inc. was a trade of 14,079 Common Stock done at an average price of $479.6 . Disclosure was reported to the exchange on Feb. 26, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Kewalramani Reshma.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 479.61 per share. | 26 Feb 2025 | 14,079 | 105,915 (0%) | 0% | 479.6 | 6,752,429 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 483.28 per share. | 24 Feb 2025 | 9,386 | 119,994 (0%) | 0% | 483.3 | 4,536,066 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 463.46 per share. | 14 Feb 2025 | 6,553 | 129,380 (0%) | 0% | 463.5 | 3,037,053 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 19,015 | 135,933 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 467.98 per share. | 10 Feb 2025 | 8,300 | 116,918 (0%) | 0% | 468.0 | 3,884,234 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 29,118 | 104,890 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 20,328 | 125,218 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 515.00 per share. | 08 Nov 2024 | 15,198 | 75,772 (0%) | 0% | 515 | 7,826,970 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 505.00 per share. | 30 Jul 2024 | 15,202 | 90,970 (0%) | 0% | 505 | 7,677,010 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 497.00 per share. | 22 Jul 2024 | 15,202 | 106,172 (0%) | 0% | 497 | 7,555,394 | Common Stock |
| Ginkgo Bioworks Holdings I... | Reshma Kewalramani | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2024 | 105,263 | 0 | - | - | Restricted Stock Units | |
| Ginkgo Bioworks Holdings I... | Reshma Kewalramani | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2024 | 105,263 | 186,002 | - | - | Class A Common Stock | |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 187.53 per share. | 24 May 2024 | 1,565 | 122,939 (0%) | 0% | 187.5 | 293,484 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 May 2024 | 1,565 | 0 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 457.00 per share. | 24 May 2024 | 1,565 | 121,374 (0%) | 0% | 457 | 715,205 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 447.00 per share. | 20 May 2024 | 15,202 | 121,374 (0%) | 0% | 447 | 6,795,294 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 431.79 per share. | 23 Feb 2024 | 9,386 | 136,507 (0%) | 0% | 431.8 | 4,052,781 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 424.01 per share. | 16 Feb 2024 | 9,359 | 152,912 (0%) | 0% | 424.0 | 3,968,310 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Kewalramani Reshma | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 420.58 per share. | 16 Feb 2024 | 7,019 | 145,893 (0%) | 0% | 420.6 | 2,952,051 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 422.74 per share. | 09 Feb 2024 | 8,255 | 162,271 (0%) | 0% | 422.7 | 3,489,719 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 26,972 | 150,199 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Kewalramani Reshma | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 20,327 | 170,526 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Kewalramani Reshma | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 14,516 | 123,227 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Kewalramani Reshma | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 407.00 per share. | 15 Dec 2023 | 17,135 | 108,711 (0%) | 0% | 407 | 6,973,945 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2023 | 14,077 | 1,565 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharmaceuticals, Inc. | Kewalramani Reshma | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 187.53 per share. | 15 Dec 2023 | 14,077 | 125,846 (0%) | 0% | 187.5 | 2,639,860 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2023 | 3,058 | 0 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharmaceuticals, Inc. | Kewalramani Reshma | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 155.57 per share. | 15 Dec 2023 | 3,058 | 111,769 (0%) | 0% | 155.6 | 475,733 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 397.00 per share. | 13 Dec 2023 | 5,098 | 108,711 (0%) | 0% | 397 | 2,023,906 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 355.00 per share. | 17 Jul 2023 | 7,828 | 118,906 (0%) | 0% | 355 | 2,778,940 | Common Stock |
| Ginkgo Bioworks Holdings I... | Reshma Kewalramani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 139,860 | 139,860 | - | - | Stock Option | |
| Ginkgo Bioworks Holdings I... | Reshma Kewalramani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 105,263 | 105,263 | - | - | Restricted Stock Units | |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 339.43 per share. | 27 Apr 2023 | 1,668 | 126,690 (0%) | 0% | 339.4 | 566,169 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 338.69 per share. | 27 Apr 2023 | 1,611 | 128,358 (0%) | 0% | 338.7 | 545,630 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 340.18 per share. | 27 Apr 2023 | 38 | 126,652 (0%) | 0% | 340.2 | 12,927 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 289.12 per share. | 24 Feb 2023 | 9,386 | 129,969 (0%) | 0% | 289.1 | 2,713,680 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 292.85 per share. | 17 Feb 2023 | 9,359 | 139,355 (0%) | 0% | 292.8 | 2,740,783 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 298.26 per share. | 10 Feb 2023 | 5,990 | 148,714 (0%) | 0% | 298.3 | 1,786,577 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 294.33 per share. | 10 Feb 2023 | 3,372 | 154,704 (0%) | 0% | 294.3 | 992,481 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 29,118 | 131,104 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 26,972 | 158,076 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 12,388 | 101,986 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 315.05 per share. | 25 Jan 2023 | 10,000 | 89,598 (0%) | 0% | 315.1 | 3,150,500 | Common Stock |
| Ginkgo Bioworks Holdings I... | Reshma Kewalramani | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2022 | 9,818 | 80,739 | - | - | Class A Common Stock | |
| Ginkgo Bioworks Holdings I... | Reshma Kewalramani | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2022 | 9,818 | 0 | - | - | Restricted Stock Units | |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 305.06 per share. | 15 Aug 2022 | 11,689 | 99,598 (0%) | 0% | 305.1 | 3,565,846 | Common Stock |
| Ginkgo Bioworks Holdings I... | Reshma Kewalramani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 108,516 | 108,516 | - | - | Stock Option | |
| Ginkgo Bioworks Holdings I... | Reshma Kewalramani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 70,921 | 70,921 | - | 0 | Class A Common Stock | |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 227.86 per share. | 24 Feb 2022 | 7,246 | 122,842 (0%) | 0% | 227.9 | 1,651,074 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 232.51 per share. | 17 Feb 2022 | 8,584 | 130,088 (0%) | 0% | 232.5 | 1,995,866 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 237.74 per share. | 10 Feb 2022 | 3,031 | 138,672 (0%) | 0% | 237.7 | 720,590 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 29,117 | 141,703 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 29,032 | 112,586 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 9,800 | 83,554 (0%) | 0% | 0 | Common Stock | |
| Ginkgo Bioworks Holdings I... | Reshma Kewalramani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 9,818 | 9,818 | - | - | Restricted Stock Units | |
| Ginkgo Bioworks Holdings I... | Reshma Kewalramani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2021 | 51,782 | 51,782 | - | - | Stock Option | |
| Ginkgo Bioworks Holdings I... | Reshma Kewalramani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2021 | 17,649 | 17,649 | - | - | Stock Option | |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Purchase of securities on an exchange or from another person at price $ 195.14 per share. | 19 Aug 2021 | 5,757 | 69,511 (0%) | 0% | 195.1 | 1,123,421 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Purchase of securities on an exchange or from another person at price $ 196.34 per share. | 19 Aug 2021 | 4,243 | 73,754 (0%) | 0% | 196.3 | 833,071 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 217.57 per share. | 24 Feb 2021 | 2,898 | 63,643 (0%) | 0% | 217.6 | 630,518 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 211.75 per share. | 17 Feb 2021 | 2,080 | 66,541 (0%) | 0% | 211.8 | 440,440 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 214.16 per share. | 10 Feb 2021 | 2,962 | 68,621 (0%) | 0% | 214.2 | 634,342 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 29,031 | 71,583 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 12,388 | 42,552 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 3,516 | 30,164 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 187.53 per share. | 06 Aug 2020 | 1,564 | 28,190 (0%) | 0% | 187.5 | 293,297 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2020 | 1,564 | 15,642 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 270.36 per share. | 06 Aug 2020 | 870 | 27,677 (0%) | 0% | 270.4 | 235,213 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2020 | 509 | 3,058 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 155.57 per share. | 06 Aug 2020 | 509 | 28,699 (0%) | 0% | 155.6 | 79,185 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 272.76 per share. | 06 Aug 2020 | 487 | 26,719 (0%) | 0% | 272.8 | 132,834 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 271.42 per share. | 06 Aug 2020 | 471 | 27,206 (0%) | 0% | 271.4 | 127,839 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 269.11 per share. | 06 Aug 2020 | 152 | 28,547 (0%) | 0% | 269.1 | 40,905 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 273.27 per share. | 06 Aug 2020 | 93 | 26,626 (0%) | 0% | 273.3 | 25,414 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 286.07 per share. | 15 May 2020 | 27 | 26,654 (0%) | 0% | 286.1 | 7,724 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 287.63 per share. | 15 May 2020 | 19 | 26,635 (0%) | 0% | 287.6 | 5,465 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 283.80 per share. | 15 May 2020 | 10 | 26,681 (0%) | 0% | 283.8 | 2,838 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 280.44 per share. | 15 May 2020 | 9 | 26,701 (0%) | 0% | 280.4 | 2,524 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 288.33 per share. | 15 May 2020 | 9 | 26,626 (0%) | 0% | 288.3 | 2,595 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 279.71 per share. | 15 May 2020 | 7 | 26,710 (0%) | 0% | 279.7 | 1,958 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 276.33 per share. | 15 May 2020 | 6 | 26,717 (0%) | 0% | 276.3 | 1,658 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 281.67 per share. | 15 May 2020 | 6 | 26,695 (0%) | 0% | 281.7 | 1,690 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 282.75 per share. | 15 May 2020 | 4 | 26,691 (0%) | 0% | 282.8 | 1,131 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 274.50 per share. | 15 May 2020 | 2 | 26,723 (0%) | 0% | 274.5 | 549 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 187.53 per share. | 06 May 2020 | 1,564 | 28,190 (0%) | 0% | 187.5 | 293,297 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2020 | 1,564 | 17,206 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 274.04 per share. | 06 May 2020 | 864 | 26,760 (0%) | 0% | 274.0 | 236,771 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 155.57 per share. | 06 May 2020 | 510 | 28,700 (0%) | 0% | 155.6 | 79,341 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2020 | 510 | 3,567 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 270.35 per share. | 06 May 2020 | 416 | 28,284 (0%) | 0% | 270.4 | 112,466 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 272.77 per share. | 06 May 2020 | 360 | 27,624 (0%) | 0% | 272.8 | 98,197 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 271.92 per share. | 06 May 2020 | 300 | 27,984 (0%) | 0% | 271.9 | 81,576 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Reshma Kewalramani | Director, CEO & President | Sale of securities on an exchange or to another person at price $ 275.17 per share. | 06 May 2020 | 134 | 26,626 (0%) | 0% | 275.2 | 36,873 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges